TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline frequency of vocal behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of clinical anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clavicular length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event free survival at 3-years follow up
Endpoint domain: Mortality/survival
Primary endpoint: Neuroendocrine Neoplasms detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Rate (CR + Cru + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Intrathoracic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell free DNA rate in serum before IVF stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell free DNA rate in follicular fluid on the day of puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Urine Glucose Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in 8-point Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Prostate-specific Antigen (PSA) >4 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self report of adequate relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Macro endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Micro endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitrate urinary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of grade 3 unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Week 26 in the Friedreich's Ataxia Rating Scale (FARS)-mNeuro Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Amplitude of Duration of Auditory Mismatch Negativity (MMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - Vss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - CL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in PROMISE 29 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rate of Intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: CA125 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune parameters (immunocytes phenotype)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUCt and Cmax of repaglinide and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net Adverse Clinical Event - NACE
Endpoint domain: Adverse events/effects
Primary endpoint: Major Adverse Cardiac Event - MACE
Endpoint domain: Adverse events/effects
Primary endpoint: Safety measured by SUSARS
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving IWG response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle belly and tendon length of the medial gastrocnemius and semitendinosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of range of motion of the ankle and knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Craniofacial Pain and Disability Inventory
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Jaw Functional Limitation Scale-8
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline achalasia symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain score after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival of ultrathin occlusal veneers
Endpoint domain: Mortality/survival
Primary endpoint: Lymphoid neogenesis features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of Oxycodone hydrochloride injection
Endpoint domain: Adverse events/effects
Primary endpoint: 2-year incidence of confirmed CTEPH
Endpoint domain: Mortality/survival
Primary endpoint: Vaginal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal cell detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expired 13CO2 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Vellus Hair Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Terminal Hair Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cumulative Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Space extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle class I cuspid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parallelism of the dental axes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experiencing an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuing From Study Treatment Due to an AE(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Time of Start of Induction of Labor to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Patient-related Tennis Elbow Questionnaire change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nicotine levels in Exhaled Breath Sample (EBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propylene glycol levels in Exhaled Breath Sample (EBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vegetable Glycerin levels in Exhaled Breath Sample (EBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbonyls levels in Exhaled Breath Sample (EBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine levels in Room Air Sample (RAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parent-rated self-control of the child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in plasma glucagon values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Spherical Equivalent Refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Duration of Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Gastric Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Recording all Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Observing pump performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improved vein graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fatty Liver Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pain by VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of CPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of 2019-nCoV
Endpoint domain: Mortality/survival
Primary endpoint: Improvement rate of 2019-nCoV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of long-term adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in frequency, severity or duration of headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration After Single Dose Administration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary excretion of Kidney injury molecule-1 (KIM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urinary excretion of Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ANI index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving at Least 4-fold Increase in Titer for TIV Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Under-Two Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Post-Partum Contraceptive Prevalence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: SCCA blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Useful hearing preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Surgical Site Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the number of tumor specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in waistline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased Inflammation Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression of Oxygenation Needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: success rate of care without severe pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: success rate of care without major side effects
Endpoint domain: Adverse events/effects
Primary endpoint: health of children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of radiation injury of the lungs
Endpoint domain: Adverse events/effects
Primary endpoint: Definition of patients with silent arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of Initial IV Placement Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EBV lytic phase activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Splint Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician Splint Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in PANSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete (R0) resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient-reported PROMIS 10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-reported Obesity-related Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported Obesity and Weight-loss Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-reported comorbidities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of observed DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IV cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IP cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported axial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fitbit wear time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Text message response rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Bone Level of dental implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in oAHI (obstructive apnea-hypopnea index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified-Yale Preoperative Anxiety Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of binge days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Intracranial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle Fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Evoked Torque after 15 minutes session of electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarettes Per Day (CPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Smoke-free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of eosinophils in nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Breast Density at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Breast Density at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Experience Grade 3 or Grade 4 Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Serum Concentration-time Curve (AUC) of FPA144
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of FPA144
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Neuromuscular Recovery (TTNMR) In Reversal of Moderate Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) Up To 7 Days Post Administration of Study Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of Postpartum Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune Response to Hepatitis B Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Device and/or Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment response assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-reported tachypsychia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quick Inventory of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Sexually Transmitted Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Multidimensional Fatigue Inventory (MFI) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Agitation/Aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VX-770 pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hemostasis Achieved at Target Bleeding Site Within 5 Minutes After Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Post-operative Re-bleeding at Target Bleeding Site Requiring Surgical Re-exploration
Endpoint domain: Adverse events/effects
Primary endpoint: Pain on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in B/Z usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cpeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in ICIQ-SF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom-free Day Measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost Measurement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Isokinetic Knee Extension Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: General safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Scale (mRS) score at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reference intervals for sonoclot analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time spent in standard sleep stages
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Early neurological deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with P. vivax CQ resistant parasite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Post-biopsy Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary artery calcium (CAC) score at Year 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CAD risk factors, Framingham Risk Score (FRS) at Year 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse cardiac outcomes during follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Plaque index from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gingivitis from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gingival bleeding from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGS Testing Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in scores of FACT/GOC-Ntx questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: B and T cell receptor repertoire (Immunome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vegetable and fruit intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ellipsoid zone disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Complete Response (CR) and Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical status information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial imaging technology evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic mutations presence testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate score of CPR quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MAT initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAT engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO2 peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes